MedElevator
Войти в исследования Pakistan journal of pharmaceutical sciences · 2026
Integrative in-silico, in-vitro and in-vivo assessment of [W4KR5]-curcumin conjugates as potential anti-inflammatory and antinociceptive therapeutics.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nazish Sohaib Syeda, Muzzammil Masaud Syed, Rasool Yasir, Imran Sajid Mohammad, Ayaz Sana, Shamim Abida, Zafar Malik Sohaib
Аннотация
BACKGROUND: Curcumin is well recognized as a natural anti-inflammatory and analgesic compound; however, its application in clinical conditions is hindered by its poor bioavailability and moderate potency. Peptide conjugation modification is a promising approach to enhance its potency.
OBJECTIVES: The purpose of this study was to design, synthesize and evaluate new cyclopeptide-curcumin conjugates to enhance cyclooxygenase inhibition, anti-inflammatory efficacy and antinociceptive effects.
METHODS: Three cyclopeptide-curcumin conjugates-[ W4KR5]-5-oxopentanoate-curcumin, [W4KR5]-3,5-dioxopentanoate-curcumin and [W4KR5]-12-oxododecanoate-curcumin-were investigated using integrated in-silico, in-vitro and in-vivo approaches. Molecular docking was performed against COX-1 (PDB ID: 3N8X) and COX-2 (PDB ID: 1PXX). In-vitro COX inhibition assays assessed enzyme selectivity. At the same time, in-vivo antinociceptive and anti-inflammatory activities were evaluated using acetic acid-induced writhing, tail immersion, formalin-induced pain and carrageenan-induced paw edema.
RESULTS: All conjugates demonstrated superior binding affinity to COX enzymes compared to curcumin, with [W4KR5]-12-oxododecanoate-curcumin exhibiting the strongest COX-2 interaction (-11.4 kcal/mol vs. -7.8 kcal/mol for curcumin), stabilized by key residues Tyr385, Ser530 and Arg120. This compound showed marked COX-2 selectivity in-vitro (IC50 = 0.82 µM) relative to COX-1 (IC50 = 4.65 µM), outperforming curcumin (COX-2 IC50 = 6.21 µM). In-vivo, it significantly reduced acetic acid-induced writhing (72.4%), increased tail immersion latency (63.1%), suppressed formalin-induced neurogenic (61.7%) and inflammatory (75.5%) pain phases and inhibited carrageenan-induced paw edema by 68.2%, compared to 39.4% for curcumin.
CONCLUSION: The conjugation of cyclopeptide significantly increases the anti-inflammatory and antinociceptive potency of curcumin. Of the tested analogs, [W4KR5]-12-oxododecanoate-curcumin is particularly noteworthy as a lead compound worthy of further studies.
OBJECTIVES: The purpose of this study was to design, synthesize and evaluate new cyclopeptide-curcumin conjugates to enhance cyclooxygenase inhibition, anti-inflammatory efficacy and antinociceptive effects.
METHODS: Three cyclopeptide-curcumin conjugates-[ W4KR5]-5-oxopentanoate-curcumin, [W4KR5]-3,5-dioxopentanoate-curcumin and [W4KR5]-12-oxododecanoate-curcumin-were investigated using integrated in-silico, in-vitro and in-vivo approaches. Molecular docking was performed against COX-1 (PDB ID: 3N8X) and COX-2 (PDB ID: 1PXX). In-vitro COX inhibition assays assessed enzyme selectivity. At the same time, in-vivo antinociceptive and anti-inflammatory activities were evaluated using acetic acid-induced writhing, tail immersion, formalin-induced pain and carrageenan-induced paw edema.
RESULTS: All conjugates demonstrated superior binding affinity to COX enzymes compared to curcumin, with [W4KR5]-12-oxododecanoate-curcumin exhibiting the strongest COX-2 interaction (-11.4 kcal/mol vs. -7.8 kcal/mol for curcumin), stabilized by key residues Tyr385, Ser530 and Arg120. This compound showed marked COX-2 selectivity in-vitro (IC50 = 0.82 µM) relative to COX-1 (IC50 = 4.65 µM), outperforming curcumin (COX-2 IC50 = 6.21 µM). In-vivo, it significantly reduced acetic acid-induced writhing (72.4%), increased tail immersion latency (63.1%), suppressed formalin-induced neurogenic (61.7%) and inflammatory (75.5%) pain phases and inhibited carrageenan-induced paw edema by 68.2%, compared to 39.4% for curcumin.
CONCLUSION: The conjugation of cyclopeptide significantly increases the anti-inflammatory and antinociceptive potency of curcumin. Of the tested analogs, [W4KR5]-12-oxododecanoate-curcumin is particularly noteworthy as a lead compound worthy of further studies.